A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Last Update: Mar 30, 2025
A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
ClinicalTrials.gov Identifier:
NCT05985915
Novartis Reference Number:CVAY736A2301E1
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]).

* The study treatment is ianalumab 300 mg in a 2 mL pre-filled syringe (PFS) or in a 2 mL autoinjector (AI) for injection. All participants will receive ianalumab either monthly or every 3 months.
* The treatment duration will be 3 years with an additional up to 2-year safety follow-up. The total duration of this extension study will be up to 5 years.
* The visit frequency will be monthly during both the treatment period and mandatory follow-up, and then less frequently during the subsequent conditional follow-up.

Treatment of interest: The randomized treatment (ianalumab) will be received monthly or every 3 months. Participants assigned to treatment every 3 months will receive placebo every month between the ianalumab doses to maintain blinding.

Number of Participants: Approximately 600 participants from the NEPTUNUS core studies will be rolled over into the extension study.

Treatment Groups:There will be no screening period in this trial. From Week 48 of the NEPTUNUS core study, participants will be given the opportunity to consent to this extension study. From Week 52 of the NEPTUNUS core studies (i.e., Day 1 in the extension study), eligible participants will be assigned to either one of the treatment regimens:

* ianalumab 300 mg monthly or
* ianalumab 300 mg once every 3 months

Participants receiving placebo in either of the NEPTUNUS core studies will be randomized 1:1 to receive ianalumab 300 mg monthly or every 3 months starting from Week 60 and participants receiving ianalumab in either of the NEPTUNUS core studies will continue the same treatment in the extension study.

Ianalumab will be given as a subcutaneous injection from a 2 mL pre-filled syringe or a 2 mL autoinjector. Participants will be given the opportunity to self-inject at home on some visits after receiving training. The primary purpose of this 3-year treatment extension study is the continued evaluation of the safety and tolerability of treatment with ianalumab 300 mg monthly or every 3 months. An additional purpose is to explore the long-term efficacy of both dosing regimens of ianalumab 300 mg.

Trial Design: This is a multicenter, randomized, double-blind, phase 3 study to assess the long-term safety and tolerability of four treatment regimens of ianalumab in participants with Sjogrens syndrome who have taken part in and completed one of two NEPTUNUS core studies, NEPTUNUS-1 (CVAY736A2301) or NEPTUNUS-2 (CVAY736A2302). There will be no screening period in this trial. From week 48 of the NEPTUNUS core study, participants will be given the opportunity to consent to this extension study. Eligible participants will continue their assigned treatment to receive ianalumab 300 mg either monthly or every 3 months for up to 3 additional years of treatment beyond the 1-year core study period. After the treatment period, all participants will enter a follow-up period to be monitored for at least 20 weeks and then a conditional (if B-cell recovery criteria have not been met) follow-up period. The total post treatment follow-up period is up to 2 years.

Study Population: Participants with Sjogrens syndrome who have completed treatment in one of two NEPTUNUS core studies.

Study treatment assignment method: Participants randomized to ianalumab 300 mg monthly or every 3 months in one of the NEPTUNUS core studies will continue their assigned treatment. Participants randomized to placebo in the NEPTUNUS core studies will be randomized in a 1:1 ratio to either ianalumab 300 mg monthly or every 3 months.

Participants randomized to ianalumab 300 mg every 3 months will receive placebo (a dummy treatment) once monthly between doses.

Committees: An independent Data Monitoring Committee (DMC) will be utilized for safety review throughout the study. A steering committee will be formed to ensure overview of the study conduct.

Condition
Sjogrens Syndrome
Phase
Phase3
Overall Status
Recruiting
Number of Participants
600
Start Date
Oct 27, 2023
Completion Date
Jul 18, 2030
Gender
All
Age(s)
18 Years - 75 Years (Adult, Older Adult)

Interventions

Drug

Ianalumab (VAY736)

Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use
Other

Placebo

Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use

Eligibility Criteria

Inclusion Criteria:

1. Signed informed consent prior to participation in the extension study.
2. Participants must have participated in either one of the two NEPTUNUS core studies, CVAY736A2301 or CVAY736A2302, and must have completed the entire treatment up to Week 48 without treatment discontinuation in core NEPTUNUS studies.
3. In the judgement of the Investigator, participants must be expected to clinically benefit from continued ianalumab therapy.

Exclusion Criteria:

1. Use of therapies excluded by the NEPTUNUS-1 and NEPTUNUS-2 study protocols (see NEPTUNUS studies protocols exclusion criteria in Section 5.2 for details).
2. Plans for administration of live vaccines during the study period.
3. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.
4. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment during dosing and for 6 months after stopping of investigational drug. Highly effective contraception methods include:

* Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
* Female bilateral tubal ligation, female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or total hysterectomy at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
* Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.
* Use of oral (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or

transdermal hormone contraception.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

Contraception should be used in accordance with locally approved prescribing information of concomitant medications administered.

Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms). Women are considered of not child-bearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child-bearing potential.

If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form (ICF).
5. United States (and other countries, if male contraception is locally required): Sexually active males, unless they agree to use barrier protection during intercourse with a woman of child-bearing potential, while taking study treatment. As condom use alone has a reported failure rate exceeding 1% per year, it is recommended that female partners of male study participants use a second method of birth control. Although ianalumab is not teratogenic and/or genotoxic, and not transferred to semen, male contraception is required, as requested by FDA.

Globally, for all sexually active males, contraception should be used in accordance with the locally approved prescribing information of concomitant medications administered.

Argentina

Novartis Investigative Site

Recruiting

Tucuman,San Miguel De Tucuman,4000,Argentina

Novartis Investigative Site

Recruiting

Buenos Aires,1646,Argentina

Novartis Investigative Site

Recruiting

Ciudad Autonoma de Bs As,C1428azf,Argentina

Novartis Investigative Site

Recruiting

Ciudad Autonoma de Bs As,Buenos Aires,C1055aaf,Argentina

Novartis Investigative Site

Recruiting

Quilmes,Buenos Aires,1878,Argentina

Australia

Novartis Investigative Site

Recruiting

Maroochydore,Queensland,4558,Australia

Novartis Investigative Site

Recruiting

Woodville South,South Australia,5011,Australia

Novartis Investigative Site

Recruiting

Hobart,Tasmania,7000,Australia

Austria

Novartis Investigative Site

Recruiting

Stockerau,2000,Austria

Novartis Investigative Site

Recruiting

Graz,8036,Austria

Belgium

Novartis Investigative Site

Recruiting

Leuven,3000,Belgium

Brazil

Novartis Investigative Site

Recruiting

Salvador,BA,40150 150,Brazil

Novartis Investigative Site

Recruiting

Vitoria,ES,29055 450,Brazil

Novartis Investigative Site

Recruiting

Juiz de Fora,MG,36010 570,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,04266 010,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,01409-902,Brazil

Bulgaria

Novartis Investigative Site

Recruiting

Burgas,8000,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1606,Bulgaria

Canada

Novartis Investigative Site

Recruiting

Rimouski,Quebec,G5l 5t1,Canada

Novartis Investigative Site

Recruiting

Sherbrooke,Quebec,J1g 2e8,Canada

Novartis Investigative Site

Recruiting

Trois Rivieres,Quebec,G9a 3y2,Canada

Novartis Investigative Site

Recruiting

Sydney,Nova Scotia,B1p 1p3,Canada

Chile

Novartis Investigative Site

Recruiting

Concepcion,6740,Chile

Novartis Investigative Site

Recruiting

Santiago,7500571,Chile

Novartis Investigative Site

Recruiting

Santiago,7500710,Chile

Novartis Investigative Site

Recruiting

Valdivia,Los Rios,5110683,Chile

Novartis Investigative Site

Recruiting

Santiago,RM,7500588,Chile

China

Novartis Investigative Site

Recruiting

Taiyuan,Shanxi,030001,China

Novartis Investigative Site

Recruiting

Chongqing,Chongqing,400010,China

Novartis Investigative Site

Recruiting

Beijing,100029,China

Novartis Investigative Site

Recruiting

Shenzhen,Guangdong,518020,China

Novartis Investigative Site

Recruiting

Beijing,100730,China

Novartis Investigative Site

Recruiting

Nanchang,Jiangxi,330006,China

Novartis Investigative Site

Recruiting

Tianjin,300052,China

Novartis Investigative Site

Recruiting

Pingxiang,Jiangxi,337000,China

Novartis Investigative Site

Recruiting

Xinxiang,453099,China

Novartis Investigative Site

Recruiting

Yinchuan City,The Ningxia Hui Autonomous Reg,750000,China

Novartis Investigative Site

Recruiting

Nanjing,Jiangsu,210008,China

Novartis Investigative Site

Recruiting

Shanghai,200011,China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510630,China

Novartis Investigative Site

Recruiting

Chang Chun,Jilin,130021,China

Colombia

Novartis Investigative Site

Recruiting

Bucaramanga,Santander,0001,Colombia

Novartis Investigative Site

Recruiting

Bogota,110221,Colombia

Novartis Investigative Site

Recruiting

Medellin,Antioquia,050001,Colombia

Novartis Investigative Site

Recruiting

Barranquilla,Atlantico,080002,Colombia

Czechia

Novartis Investigative Site

Recruiting

Brno,63800,Czechia

Novartis Investigative Site

Recruiting

Uherske Hradiste,686 01,Czechia

France

Novartis Investigative Site

Recruiting

Dijon,21034,France

Novartis Investigative Site

Recruiting

Lille,59037,France

Novartis Investigative Site

Recruiting

Le Mans,72000,France

Novartis Investigative Site

Recruiting

Paris cedex 10,75010,France

Novartis Investigative Site

Recruiting

Paris,75013,France

Novartis Investigative Site

Recruiting

Strasbourg,67000,France

Novartis Investigative Site

Recruiting

Angers Cedex 9,49933,France

Novartis Investigative Site

Recruiting

Brest,29200,France

Novartis Investigative Site

Recruiting

Le Kremlin Bicetre,94275,France

Germany

Novartis Investigative Site

Recruiting

Hannover,30625,Germany

Novartis Investigative Site

Recruiting

Koeln,50937,Germany

Novartis Investigative Site

Recruiting

Ludwigshafen,67063,Germany

Novartis Investigative Site

Recruiting

Berlin,13353,Germany

Novartis Investigative Site

Recruiting

Dresden,01307,Germany

Novartis Investigative Site

Recruiting

Erlangen,91056,Germany

Novartis Investigative Site

Recruiting

Freiburg,79106,Germany

Greece

Novartis Investigative Site

Recruiting

Athens,115 27,Greece

Guatemala

Novartis Investigative Site

Recruiting

Quetzaltenango,9001,Guatemala

Novartis Investigative Site

Recruiting

Guatemala,01010,Guatemala

Novartis Investigative Site

Recruiting

Guatemala City,01011,Guatemala

Hungary

Novartis Investigative Site

Recruiting

Szekesfehervar,Fejer,8000,Hungary

Novartis Investigative Site

Recruiting

Debrecen,4032,Hungary

Novartis Investigative Site

Recruiting

Eger,3300,Hungary

Novartis Investigative Site

Recruiting

Gyula,5700,Hungary

Novartis Investigative Site

Recruiting

Szeged,6720,Hungary

India

Novartis Investigative Site

Recruiting

Ahmedabad,Gujarat,380013,India

Novartis Investigative Site

Recruiting

Ahmedabad,Gujarat,380015,India

Novartis Investigative Site

Recruiting

New Delhi,110029,India

Israel

Novartis Investigative Site

Recruiting

Kfar Saba,44281,Israel

Novartis Investigative Site

Recruiting

Ramat Gan,52621,Israel

Italy

Novartis Investigative Site

Recruiting

Ancona,AN,60126,Italy

Novartis Investigative Site

Recruiting

Napoli,80131,Italy

Novartis Investigative Site

Recruiting

Salerno,SA,84100,Italy

Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,455-8530,Japan

Novartis Investigative Site

Recruiting

Meguro-ku,Tokyo,152-8902,Japan

Novartis Investigative Site

Recruiting

Kuwana,Mie,511-0061,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,457 8510,Japan

Novartis Investigative Site

Recruiting

Shinjuku-ku,Tokyo,160 8582,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,457-8511,Japan

Novartis Investigative Site

Recruiting

Kitakyushu,Fukuoka,807-8556,Japan

Novartis Investigative Site

Recruiting

Yokohama,Kanagawa,245-8575,Japan

Novartis Investigative Site

Recruiting

Sasebo,Nagasaki,857-1195,Japan

Novartis Investigative Site

Recruiting

Chuo ku,Tokyo,104 8560,Japan

Novartis Investigative Site

Recruiting

Itabashi-ku,Tokyo,173-8610,Japan

Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,Seocho Gu,06591,Korea, Republic of

Novartis Investigative Site

Recruiting

Gwangju,61469,Korea, Republic of

Lithuania

Novartis Investigative Site

Recruiting

Vilnius,08406,Lithuania

Mexico

Novartis Investigative Site

Recruiting

Culiacan,Sinaloa,Cp 80000,Mexico

Novartis Investigative Site

Recruiting

Merida,Yucatan,97070,Mexico

Novartis Investigative Site

Recruiting

Mexico,07029,Mexico

Novartis Investigative Site

Recruiting

Ciudad de Mexico,Distrito Federal,06700,Mexico

Novartis Investigative Site

Recruiting

Guadalajara,Jalisco,44650,Mexico

Poland

Novartis Investigative Site

Recruiting

Krakow,30 002,Poland

Novartis Investigative Site

Recruiting

Warszawa,00-874,Poland

Novartis Investigative Site

Recruiting

Wroclaw,Dolnoslaskie,52-210,Poland

Novartis Investigative Site

Recruiting

Krakow,Malopolskie,30-727,Poland

Novartis Investigative Site

Recruiting

Poznan,Wielkopolskie,61-397,Poland

Portugal

Novartis Investigative Site

Recruiting

Guarda,6300 858,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1050-034,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1349-019,Portugal

Novartis Investigative Site

Recruiting

Braga,4710243,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1649 035,Portugal

Romania

Novartis Investigative Site

Recruiting

Brasov,500283,Romania

Novartis Investigative Site

Recruiting

Cluj Napoca,400006,Romania

Singapore

Novartis Investigative Site

Recruiting

Singapore,S308433,Singapore

Slovakia

Novartis Investigative Site

Novartis Investigative Site

Recruiting

Bratislava,81108,Slovakia

South Africa

Novartis Investigative Site

Recruiting

Stellenbosch,7600,South Africa

Novartis Investigative Site

Recruiting

Panorama,7500,South Africa

Spain

Novartis Investigative Site

Recruiting

La Coruna,Galicia,15006,Spain

Novartis Investigative Site

Recruiting

Bilbao,Pais Vasco,48013,Spain

Novartis Investigative Site

Recruiting

Cordoba,Andalucia,14004,Spain

Novartis Investigative Site

Recruiting

Vigo,Pontevedra,36200,Spain

Novartis Investigative Site

Recruiting

Barcelona,08041,Spain

Novartis Investigative Site

Recruiting

Madrid,28034,Spain

Novartis Investigative Site

Recruiting

Sabadell,Barcelona,08208,Spain

Novartis Investigative Site

Recruiting

Santander,Cantabria,39008,Spain

Sweden

Novartis Investigative Site

Recruiting

Stockholm,SE,113 65,Sweden

Taiwan

Novartis Investigative Site

Recruiting

Taichung,40447,Taiwan

Novartis Investigative Site

Recruiting

Taichung,407219,Taiwan

Novartis Investigative Site

Recruiting

Kaohsiung,83301,Taiwan

Novartis Investigative Site

Recruiting

Kaohsiung,81346,Taiwan

Turkey

Novartis Investigative Site

Recruiting

Ankara,06100,Turkey

Novartis Investigative Site

Recruiting

Ankara,06230,Turkey

Novartis Investigative Site

Recruiting

Ankara,06500,Turkey

Novartis Investigative Site

Recruiting

Kocaeli,41380,Turkey

United Kingdom

Novartis Investigative Site

Recruiting

Leeds,Ls1 3ex,United Kingdom

Novartis Investigative Site

Recruiting

Liverpool,L9 7al,United Kingdom

Novartis Investigative Site

Recruiting

Newcastle Upon Tyne,Ne1 4lp,United Kingdom

United States

West Broward Rheumatology Associates Inc

Recruiting

Tamarac,Florida,33321,United States

Alan R Alberts

Natasia Wilson

Phone: 954-545-8400
Email: n.wilsonwbra@gmail.com

On Site Clinical Solutions Llc

Recruiting

Charlotte,North Carolina,28202,United States

Roshini Narayanaswamy

Phone: 800-785-3150
Email: rnara@onsiteclinical.com

Rakesh C Patel

Advanced Rheumatology of Houston

Recruiting

Spring,Texas,77382,United States

Gabby Obeidat

Phone: 281-766-7886
Email: gabby@advancedrheum.com

Tamar Brionez

Tufts School of Dental Medicine

Recruiting

Boston,Massachusetts,02111,United States

Katherine Vogt

Phone: 617-636-2408
Email: katherine.vogt@tufts.edu

Athena Papas

North GA Rheumatology Group PC

Recruiting

Suwanee,Georgia,30024,United States

Jerry Wilkerson

Phone: 770-822-1090
Email: Jerry.Wilkerson@ngrgroup.net

Theresa Lawrence Ford

Altoona Center for Clin Res

Recruiting

Duncansville,Pennsylvania,16635,United States

Alan J Kivitz

Mary Beyer

Email: marybeyer@altoonaresearch.com

Prolato Clinical Research Center

Recruiting

Houston,Texas,77054,United States

Asma Patwary

Phone: 832-338-9118
Email: apatwary@prolato.org

Sreedhar Mandayam

RAO Research LLS

Recruiting

Oklahoma City,Oklahoma,73116,United States

Emma Hendrix

Phone: 405-608-8060
Email: ehendrix@raoklahoma.com

Latisha Heinlen

Arthritis Osteoporosis Assoc of NM

Recruiting

Las Cruces,New Mexico,88011,United States

Arthur Snyder

Maria Rodriguez

Phone: 575-571-7529
Email: mariar@arthritisnm.com

Clin Invest Specialists Inc

Recruiting

Orland Park,Illinois,60467,United States

Cory Conniff

Iryna Shevchuk

Phone: 847-599-2492
Email: ishevchuk@cisresearch.com

The John Hopkins Jerome L Greene Sjogren

Recruiting

Baltimore,Maryland,21224,United States

Jennifer Reed

Phone: 410-550-1887
Email: jreed52@jhu.edu

Thomas Grader Beck

Arthritis Northwest PLLC

Recruiting

Spokane,Washington,99204,United States

Phone: 509-838-6500

Christopher C Wright

Advanced Medical Research

Recruiting

La Palma,California,90623,United States

Gerald Ho

Reza Azadegan

Phone: 562-867-8195
Email: razadegan@advmedresearch.com

West Tennessee Research Institute

Recruiting

Jackson,Tennessee,38305,United States

Jacob A. Aelion

Kim Smith

Phone: 731-664-7824
Email: ksmith@arthritisclinic.org

Houston Rheumatology & Arthrit

Recruiting

Katy,Texas,77494,United States

Priyadarshini Gopal

Phone: 281-944-3610
Email: priyadarshini@biopharmainfo.net

Tara Jabeen Rizvi

Providence Medical Foundation

Recruiting

Fullerton,California,92835,United States

Angela Gonzalez

Phone: 714-992-3000
Email: Angela.Gonzalez@stjoe.org

Shirley Pang

University of Kansas Hospital

Recruiting

Kansas City,Kansas,66160,United States

Ghaith Noaiseh

Vanessa Verschelden

Phone: 913-588-9600
Email: vbarrientos@kumc.edu

Shelby Research LLC

Recruiting

Memphis,Tennessee,38119,United States

Anitha Das

Phone: 901-681-9670
Email: shelbyres1957@outlook.com

Ramesh C Gupta

Winthrop University Hospital

Recruiting

Mineola,New York,11501,United States

Monica Benitez

Phone: 516-663-2929
Email: Monica.Benitez@nyulangone.org

Steven Carsons

St Lawrence Health System

Recruiting

Potsdam,New York,13676,United States

Brittany Geiler

Phone: 315-261-5611
Email: brittany.geiler@rochesterregional.org

Eyal Kedar

Ochsner Health System

Recruiting

Baton Rouge,Louisiana,70809,United States

Phone: 225-761-5375

Saravanan Thiagarajan

Arthritis and Osteoporosis

Recruiting

Charlotte,North Carolina,28207,United States

Phone: +1 704 342 0252#1170

Gordon K W Lam

Bay Area Arthritis And Osteoporosis

Recruiting

Brandon,Florida,33511,United States

Phone: 813-651-4441

Vipul Joshi

GNP Research

Recruiting

Hollywood,Florida,33024,United States

Mark Jaffe

Rossana Villaverde

Phone: 754-248-3538
Email: rossana@gnpresearch.com

Baylor College Of Medicine

Recruiting

Houston,Texas,77030,United States

Araceli Boan

Email: Araceli.Boan@bcm.com

Rashmi Maganti

First Outpatient Research Unit

Recruiting

San Antonio,Texas,78229,United States

Phone: 210-567-0450

Agustin Escalante

Sarasota Arthritis Res Ctr

Recruiting

Sarasota,Florida,34239,United States

Phone: 941-366-1244

Kimberly Lyn Shue

STAT Research Inc

Recruiting

Dayton,Ohio,45402,United States

Leah Hedleston

Phone: 937-223-4229
Email: leah.hedleston@statresearch.com

Sanford Wolfe

Precision Comprehensive Research

Recruiting

Colleyville,Texas,76034,United States

Akhil Gangasani

Phone: 972-299-8399
Email: akhilgangasani@pccrsolutions.com

Dhiman Basu

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +41613241111
Email:

Novartis Pharmaceuticals

Phone: 1-888-669-6682
Email: novartis.email@novartis.com

Source URL: *https://prod1.novartis.com/clinicaltrials/study/nct05985915*

List of links present in page

1. https://clinicaltrials.gov/ct2/show/NCT05985915
2. #trial-eligibility
3. tel:954-545-8400

4. mailto:n.wilsonwbra@gmail.com
5. tel:800-785-3150
6. mailto:rnara@onsiteclinical.com
7. tel:281-766-7886
8. mailto:gabby@advancedrheum.com
9. tel:617-636-2408
10. mailto:katherine.vogt@tufts.edu
11. tel:770-822-1090
12. mailto:Jerry.Wilkerson@ngrgroup.net
13. mailto:marybeyer@altoonaresearch.com
14. tel:832-338-9118
15. mailto:apatwary@prolato.org
16. tel:405-608-8060
17. mailto:ehendrix@raoklahoma.com
18. tel:575-571-7529
19. mailto:mariar@arthritisnm.com
20. tel:847-599-2492
21. mailto:ishevchuk@cisresearch.com
22. tel:410-550-1887
23. mailto:jreed52@jhu.edu
24. tel:509-838-6500
25. tel:562-867-8195
26. mailto:razadegan@advmedresearch.com
27. tel:731-664-7824
28. mailto:ksmith@arthritisclinic.org
29. tel:281-944-3610
30. mailto:priyadarshini@biopharmainfo.net
31. tel:714-992-3000
32. mailto:Angela.Gonzalez@stjoe.org
33. tel:913-588-9600
34. mailto:vbarrientos@kumc.edu
35. tel:901-681-9670
36. mailto:shelbyres1957@outlook.com
37. tel:516-663-2929
38. mailto:Monica.Benitez@nyulangone.org
39. tel:315-261-5611
40. mailto:brittany.geiler@rochesterregional.org
41. tel:225-761-5375
42. tel:+1 704 342 0252#1170
43. tel:813-651-4441
44. tel:754-248-3538
45. mailto:rossana@gnpresearch.com
46. mailto:Araceli.Boan@bcm.com
47. tel:210-567-0450
48. tel:941-366-1244
49. tel:937-223-4229
50. mailto:leah.hedleston@statresearch.com
51. tel:972-299-8399
52. mailto:akhilgangasani@pccrsolutions.com
53. tel:+41613241111
54. mailto:
55. tel:1-888-669-6682
56. mailto:novartis.email@novartis.com